Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Ubiquitination of the Epstein–Barr virus-encoded latent membrane protein 1 depends on the integrity of the TRAF binding site

Abstract

The latent membrane protein 1 (LMP1) encoded by the Epstein–Barr virus functions as a constitutively activated receptor of the tumor necrosis factor receptor family. LMP1 is a short-lived protein that is ubiquitinated and degraded by the proteasome. We have previously shown that LMP1 recruits the adapter protein tumor necrosis factor receptor-associated factor 3 (TRAF3) to lipid rafts. To test if TRAFs are involved in LMP1's ubiquitination, we have mutated the LMP1 CTAR1 site that has been identified as a TRAF binding site. We show that the CTAR1 mutant (CTAR1) is expressed after transfection at a similar level to wild-type LMP1, and behaves as wild-type LMP1 with respect to membrane localization. However, CTAR1 does not bind TRAF3. We demonstrate that ubiquitination of CTAR1 is significantly reduced when compared to wild-type LMP1. In addition, the expression of wild-type LMP1 induces the ubiquitination, an effect that is significantly reduced when the CTAR1 is expressed. Taken together, our results suggest that TRAF proteins are involved in the ubiquitination of LMP1, and that their binding to LMP1 may facilitate their own ubiquitination.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Aviel S, Winberg G, Massucci M and Ciechanover A . (2000). J. Biol. Chem., 275, 23491–23499.

  • Baichwal VR and Sugden B . (1987). J. Virol., 61, 866–875.

  • Baichwal VR and Sugden B . (1988). Oncogene, 2, 461–467.

  • Bradley JR and Pober JS . (2001). Oncogene, 20, 6482–6491.

  • Brown DA and London E . (1998). Annu. Rev. Cell Dev. Biol., 14, 111–136.

  • Brown KD, Hostager BS and Bishop GA . (2001). J. Exp. Med., 193, 943–954.

  • Cherukuri A, Dykstra M and Pierce SK . (2001). Immunity, 14, 657–660.

  • Chung JY, Park YC, Ye H and Wu H . (2002). J. Cell Sci., 115, 679–688.

  • Ciechanover A, Orian A and Schwartz AL . (2000). J. Cell.Biochem. Suppl., 34, 40–51.

  • Clausse B, Fizazi K, Walczak V, Tetaud C, Wiels J, Tursz T and Busson P . (1997). Virology, 228, 285–293.

  • Deng L, Wang C, Spencer E, Yang L, Braun A, You J, Slaughter C, Pickart C and Chen ZJ . (2000). Cell, 103, 351–361.

  • Hammarskjold ML and Simurda MC . (1992). J. Virol., 66, 6496–6501.

  • Hicke L . (1999). Trends Cell Biol., 9, 107–112.

  • Higuchi M, Izumi KM and Kieff E . (2001). Proc. Natl. Acad. Sci. USA, 98, 4675–4680.

  • Hofmann RM and Pickart CM . (2001). J. Biol. Chem., 276, 27936–27943.

  • Ilangumaran S, He HT and Hoessli DC . (2000). Immunol. Today, 21, 2–7.

  • Joazeiro CA and Weissman AM . (2000). Cell, 102, 549–552.

  • Kulwichit W, Edwards RH, Davenport EM, Baskar JF, Godfrey V and Raab-Traub N . (1998). Proc. Natl. Acad. Sci. USA, 95, 11963–11968.

  • Lafont F and Simons K . (2001). Proc. Natl. Acad. Sci. USA, 98, 3180–3184.

  • Li X, Yang Y and Ashwell JD . (2002). Nature, 416, 345–347.

  • Mann KP and Thorley-Lawson D . (1987). J. Virol., 61, 2100–2108.

  • Martin J and Sugden B . (1991). J. Virol., 65, 3246–3258.

  • Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C and Kieff E . (1995). Cell, 80, 389–399.

  • Polekhina G, House CM, Traficante N, Mackay JP, Relaix F, Sassoon DA, Parker MW and Bowtell DD . (2002). Nat. Struct. Biol., 9, 68–75.

  • Rothenberger S, Rousseaux M, Knecht H, Bender FC, Legler DF and Bron C . (2002). Cell Mol. Life Sci., 59, 171–180.

  • Simons K and Toomre D . (2000). Nat.Mol.Cell Biol., 1, 31–38.

  • Strous GJ and Govers R . (1999). J. Cell Sci., 112(Pt 10), 1417–1423.

  • Wajant H, Henkler F and Scheurich P . (2001). Cell Signal., 13, 389–400.

  • Wang C, Deng L, Hong M, Akkaraju GR, Inoue J and Chen ZJ . (2001). Nature, 412, 346–351.

  • Wang D, Liebowitz D and Kieff E . (1985). Cell, 43, 831–840.

  • Ye H, Park YC, Kreishman M, Kieff E and Wu H . (1999). Mol. Cell, 4, 321–330.

Download references

Acknowledgements

The Swiss National Science Foundation (SNSF 31-61960.00) has supported this work. We thank Dr P Shaw and Dr M Thome for a critical reading of the manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sylvia Rothenberger.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rothenberger, S., Burns, K., Rousseaux, M. et al. Ubiquitination of the Epstein–Barr virus-encoded latent membrane protein 1 depends on the integrity of the TRAF binding site. Oncogene 22, 5614–5618 (2003). https://doi.org/10.1038/sj.onc.1206497

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206497

Keywords

This article is cited by

Search

Quick links